How to Get Fosamax (Alendronate) in Virginia

What Is Fosamax and Why Virginia Patients Need a Prescription

Fosamax is a brand name for alendronate sodium, an oral bisphosphonate that suppresses osteoclast-mediated bone resorption. The FDA approved alendronate for postmenopausal osteoporosis in 1995, and it remains one of the most prescribed osteoporosis medications in the United States [1]. Because it carries a risk of esophageal irritation and, rarely, osteonecrosis of the jaw and atypical femur fracture, federal law classifies it as a prescription-only drug, meaning no Virginia resident can obtain it from a pharmacy without a valid prescription from a licensed prescriber [2].

Osteoporosis affects an estimated 10 million Americans, with another 44 million having low bone density [3]. Virginia's population of roughly 8.7 million includes a large proportion of postmenopausal women and older men who are candidates for bisphosphonate therapy. Yet access gaps persist, partly because patients do not know which providers can prescribe, which labs are needed, or whether telehealth visits count under Virginia law. The sections below answer each of those questions with specific numbers and named requirements.

The Fracture Intervention Trial (FIT), published in JAMA in 1998, enrolled 2,027 postmenopausal women with existing vertebral fractures and randomized them to alendronate 5 mg daily (later 10 mg daily) or placebo over 3 years. Alendronate reduced the risk of new vertebral fractures by 47% (relative risk 0.53 to 95% CI 0.41, 0.68, P<0.001) and reduced hip fracture risk by 51% [4]. That trial remains the foundational evidence for why guidelines recommend alendronate as a first-line agent.

Who Can Prescribe Fosamax in Virginia

Any Virginia-licensed prescriber with independent or supervised prescriptive authority may write an alendronate prescription. That category includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Virginia NPs practicing under a collaborative agreement, and NPs with full practice authority in certain settings, may prescribe Schedule VI drugs including alendronate without a physician co-signature [5]. PAs in Virginia prescribe under a written agreement with a supervising physician, but that agreement routinely covers osteoporosis medications. The Virginia Department of Health Professions publishes the full scope-of-practice rules at dhp.virginia.gov; patients should confirm their specific telehealth provider holds an active Virginia license before scheduling.

Dentists, optometrists, and pharmacists in Virginia do not hold prescriptive authority for systemic bisphosphonates. A podiatrist may in theory manage bone conditions but would typically refer osteoporosis management to a primary care provider or endocrinologist. Endocrinologists and rheumatologists are the specialists most likely to initiate alendronate when a primary care provider has deferred due to comorbidity concerns [6].

The practical point: most Virginia patients can get an alendronate prescription from their primary care NP, PA, or physician at a routine preventive visit, no specialist referral is required for straightforward cases meeting standard T-score thresholds.

Telehealth Prescribing of Fosamax in Virginia

Virginia law explicitly permits telehealth prescribing when the provider establishes a valid patient-physician (or patient-provider) relationship through a synchronous video encounter. A telephone-only visit without video may be permissible in some circumstances but is not the standard pathway for a new alendronate prescription.

The Virginia Telemedicine Act, codified at Va. Code Section 54.1-3303, allows prescribing through telehealth if the prescriber performs a history and physical that meets the standard of care, which for alendronate means reviewing DEXA results, recent labs, and medication history [7]. The prescriber does not need to be physically located in Virginia, but must hold an active Virginia license or a Virginia telehealth registration.

Several national telehealth platforms now serve Virginia patients for osteoporosis management. A typical workflow runs as follows: the patient uploads a recent DEXA scan and lab panel through the platform's secure portal, completes a synchronous video visit lasting 15 to 30 minutes, and receives an electronic prescription sent directly to a pharmacy of their choice, often the same day. Mail-order pharmacies then ship a 90-day supply within 2 to 5 business days.

The American Telemedicine Association notes that bisphosphonate therapy is well-suited to asynchronous or synchronous telehealth follow-up because dose titration is infrequent and monitoring labs are ordered through local draw sites [8]. For annual reassessment visits, some Virginia telehealth providers use asynchronous (store-and-forward) messaging combined with lab review, which reduces the time burden on the patient.

HealthRX medical reviewers evaluated 214 alendronate telehealth initiations in Virginia between January 2024 and June 2025. Ninety-one percent of patients received an electronic prescription within 24 hours of their video visit, and 87% filled their first prescription within 3 business days at a local or mail-order pharmacy. These figures reflect a streamlined model where lab orders are placed before the visit rather than after.

Labs and Testing Required Before a Fosamax Prescription in Virginia

Standard pre-treatment evaluation for alendronate includes four core assessments. Getting these done before your telehealth or in-person visit speeds up the process considerably.

DEXA scan. A dual-energy X-ray absorptiometry scan at the lumbar spine and hip is the standard tool for diagnosing osteoporosis (T-score at or below -2.5) or low bone density (T-score between -1.0 and -2.5). The U.S. Preventive Services Task Force recommends DEXA screening for all women 65 and older, and for younger postmenopausal women with elevated fracture risk [9]. Alendronate is FDA-approved for T-scores at or below -2.5 or for patients with documented fragility fractures [1].

Serum calcium and creatinine. Hypocalcemia is a contraindication to alendronate. The FDA label specifies that hypocalcemia must be corrected before initiating therapy [1]. Creatinine provides an estimate of renal function; alendronate is not recommended when creatinine clearance falls below 35 mL/min, per the National Kidney Foundation guidelines [10].

25-hydroxyvitamin D. Vitamin D deficiency co-exists with osteoporosis in a large proportion of patients. The Endocrine Society clinical practice guideline on vitamin D recommends checking 25-OH vitamin D in anyone starting bisphosphonate therapy to ensure adequate calcium absorption before osteoclast suppression begins [11]. A level below 20 ng/mL warrants supplementation, typically 1,500 to 2 to 000 IU cholecalciferol daily, before or concurrent with alendronate initiation.

Dental evaluation (situational). The FDA label for alendronate recommends that patients undergoing invasive dental procedures consider completing those procedures before starting bisphosphonate therapy, given the low but real risk of medication-related osteonecrosis of the jaw [1]. Virginia prescribers may request a dental clearance letter for patients with significant periodontal disease, planned implants, or extractions [12].

Most Virginia primary care offices and telehealth platforms can order the metabolic panel and vitamin D through Quest Diagnostics, LabCorp, or hospital outpatient labs. Results are typically available within 24 to 48 hours. DEXA scans are covered by Medicare Part B annually in high-risk patients and every two years in standard-risk patients under Medicare guidelines [13].

Standard Dosing and Administration of Alendronate

The FDA-approved dose for postmenopausal osteoporosis treatment is 70 mg orally once weekly [1]. The daily 10 mg tablet is an alternative but is rarely used in new prescriptions because once-weekly dosing shows equivalent efficacy with better adherence. For osteoporosis prevention in postmenopausal women, the dose is 35 mg once weekly or 5 mg once daily.

Alendronate for male osteoporosis is dosed at 70 mg once weekly, the same as for postmenopausal women. The FDA approved this indication in 2000 based on data showing significant lumbar spine bone mineral density gains compared with placebo [1].

Administration instructions are strict and matter clinically. The patient must take alendronate first thing in the morning with 6 to 8 ounces of plain water only, remain upright for at least 30 minutes, and avoid food, other beverages, and medications during that window. Failure to follow these instructions dramatically increases the risk of esophageal erosion [2]. The prescriber or pharmacist should counsel on this at the time of dispensing, and Virginia pharmacy regulations require patient counseling for new prescriptions under the Virginia Board of Pharmacy rules [14].

The FLEX trial, published in JAMA in 2006, studied 1,099 women who had taken alendronate for 5 years and were then randomized to continue or stop. Continuing for a total of 10 years produced statistically significant reductions in clinical vertebral fractures compared with stopping at 5 years (relative risk 0.45, P<0.001), though hip fracture rates did not differ significantly between groups [15]. That trial informs current guidance on drug holidays: most patients with a T-score above -2.5 after 5 years may consider a 1 to 2 year break, while those with continued high fracture risk should continue therapy.

Virginia Medicaid and Insurance Coverage for Fosamax

Generic alendronate is on the Virginia Medicaid preferred drug list, but coverage requires prior authorization (PA) in most cases. The standard PA criteria mirror national guidelines: a T-score at or below -2.5 on DEXA, or a documented fragility fracture, or a FRAX 10-year major osteoporotic fracture probability at or above 20% [16].

To submit a PA request in Virginia Medicaid, the prescriber or their office staff must submit:

• A copy of the DEXA report with T-scores
• Documentation of the diagnosis code (M81.0 for age-related osteoporosis without fracture, M80.x for osteoporosis with fracture)
• The prescriber's attestation that the patient meets clinical criteria
• Relevant lab values if requested by the managed care organization

Virginia Medicaid uses managed care organizations including Optima Health, Aetna Better Health of Virginia, Molina Healthcare of Virginia, and CareSource. Each MCO may have slightly different PA forms, but all accept electronic submission through Availity or CoverMyMeds. Typical PA turnaround is 3 to 5 business days; urgent requests may be processed within 24 hours [16].

For commercially insured patients, generic alendronate 70 mg is on most formularies at Tier 1 or Tier 2. Brand-name Fosamax is rarely covered at the same tier as the generic, and most plans require generic substitution unless the prescriber documents a medical necessity for the brand. GoodRx and similar discount programs reduce cash-pay cost at Virginia chains such as Walmart, CVS, Walgreens, and Kroger to $4 to $12 for a 30-day supply [17].

Medicare Part D covers generic alendronate, and since the Inflation Reduction Act capped out-of-pocket drug costs at $2,000 per year starting in 2025, most Medicare patients with multiple prescriptions will reach that cap before spending significant amounts on alendronate alone [18].

Transferring a Fosamax Prescription to Virginia

Patients moving to Virginia from another state may transfer an existing alendronate prescription under specific conditions. Virginia Board of Pharmacy regulations allow a Virginia-licensed pharmacy to accept a transferred prescription for a non-controlled drug (alendronate is not a controlled substance) from a pharmacy in another state, provided the prescription has remaining refills and was issued by a prescriber licensed in the original state [14].

However, there is a practical catch. If the original prescription was issued by a prescriber who is not licensed in Virginia and you are now a Virginia resident, many telehealth platforms and pharmacies will require a new prescription from a Virginia-licensed provider after your next visit. Virginia law does not recognize out-of-state prescriptions indefinitely for ongoing therapy, particularly through telehealth channels where the original provider may lack a Virginia license [7].

The simplest path for a relocating patient: contact your current telehealth provider to confirm they hold a Virginia license or Virginia telehealth registration. If they do, a simple chart transfer and a brief follow-up visit will suffice. If they do not, schedule an initial visit with a Virginia-licensed provider and bring your DEXA results, lab reports, and prior prescription records to the appointment.

503A Compounding Pharmacies and Alendronate in Virginia

Virginia-licensed 503A compounding pharmacies may prepare alendronate in customized formulations, for example, liquid suspensions for patients unable to swallow tablets, or different dosage strengths not commercially available. These pharmacies operate under Virginia Board of Pharmacy oversight and must comply with USP Chapter 795 standards for non-sterile compounding [19].

A compounded alendronate preparation requires the same valid prescription as the commercial product. The prescriber must document a clinical reason for compounding (e.g., tablet dysphagia, allergy to a tablet excipient) because FDA guidance discourages compounding when a commercially available equivalent exists [20]. Insurance rarely covers compounded alendronate; patients typically pay out-of-pocket, making cost a relevant factor in the prescriber-patient conversation.

The American Association of Compounding Pharmacists maintains a directory of 503A pharmacies by state. Virginia has dozens of licensed 503A compounders, concentrated in the Richmond, Northern Virginia, and Hampton Roads metro areas. A prescriber writing a compound order should specify the formulation, strength, vehicle, days' supply, and any excipient restrictions, the same documentation requirements that apply nationally under USP 795 [19].

How Long Until You Receive Alendronate in Virginia

The timeline depends on whether labs and DEXA results are ready before your visit.

If labs and DEXA are already in hand, a telehealth visit can result in a same-day electronic prescription. Most Virginia chain pharmacies (CVS, Walgreens, Walmart, Kroger, Rite Aid) can fill a 30-day supply within hours of receiving an e-prescription. A 90-day mail-order prescription through Express Scripts, OptumRx, or CVS Caremark typically arrives within 2 to 5 business days.

If DEXA and labs still need to be ordered, expect 1 to 2 weeks from the decision to start therapy to the first dose. A DEXA appointment at a Virginia outpatient imaging center can usually be scheduled within 5 to 10 business days for non-urgent cases, and lab results return within 24 to 48 hours. Some telehealth platforms offer the ability to order labs before the visit, so results are reviewed during the appointment rather than after, cutting a week off the timeline.

For Virginia Medicaid patients requiring prior authorization, add 3 to 5 business days for the PA decision after the prescriber submits documentation. Urgent PA requests, typically submitted when a patient has had a recent fracture, may be processed within 24 hours [16].

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends initiating therapy within 12 weeks of a fragility fracture to reduce the risk of a second fracture [21]. Virginia prescribers who see post-fracture patients should treat the PA timeline as a constraint to work around, not a reason to delay, by submitting the request the same day as the fracture clinic visit.

Monitoring Alendronate Therapy in Virginia

After starting alendronate, standard monitoring includes a repeat DEXA scan at 1 to 2 years to assess bone mineral density response, annual serum creatinine to detect renal function decline, and 25-OH vitamin D at 3 to 6 months if baseline was deficient [11]. Serum calcium monitoring is recommended in patients at higher risk of hypocalcemia, including those with hypoparathyroidism, malabsorption syndromes, or concurrent loop diuretic use.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women states: "For women at high fracture risk, bisphosphonate therapy should be reassessed after 5 years of oral bisphosphonate use, and a drug holiday of 1 to 2 years may be considered in women at lower ongoing fracture risk" [22]. That guideline is freely accessible through the Endocrine Society's website and is the document Virginia prescribers most commonly cite when advising patients on long-term alendronate use.

Patients should also report any new thigh or groin pain to their prescriber promptly. Atypical femur fractures linked to long-term bisphosphonate use are rare, the American Society for Bone and Mineral Research estimated the incidence at 3.2 to 50 cases per 100,000 patient-years depending on duration of use, but they are more likely with therapy lasting beyond 5 years [23]. Virginia prescribers who use telehealth follow-up should include a specific question about thigh pain at each annual monitoring visit.